TCGA-BH-A208-01A-11R-A157-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
- ANGIOGENESIS+0.560
- UV_RESPONSE_DN+0.500
- HEDGEHOG_SIGNALING+0.480
- TGF_BETA_SIGNALING+0.470
- COAGULATION+0.450
- KRAS_SIGNALING_UP+0.400
- APICAL_JUNCTION+0.390
- MYOGENESIS+0.370
- NOTCH_SIGNALING+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- MYC_TARGETS_V1-0.540
- E2F_TARGETS-0.490
- DNA_REPAIR-0.450
- G2M_CHECKPOINT-0.440
- OXIDATIVE_PHOSPHORYLATION-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- MTORC1_SIGNALING-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.945 |
| 2 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.943 |
| 3 | GSM6454738 | — | A | 0.933 |
| 4 | TCGA-EW-A2FR-01A-11R-A21T-07 | — | C | 0.925 |
| 5 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.922 |
| 6 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.917 |
| 7 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.916 |
| 8 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.911 |
| 9 | SRR8518425 | — | A | 0.906 |
| 10 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.680 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |